Citi's Global Industrial Tech & Mobility Conference 2026
Logotype for Mirion Technologies Inc

Mirion Technologies (MIR) Citi's Global Industrial Tech & Mobility Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Mirion Technologies Inc

Citi's Global Industrial Tech & Mobility Conference 2026 summary

18 Feb, 2026

Strategic growth and market trends

  • Nuclear power segment now represents 47% of revenue, with a presence in over 95% of the global operating base, driven by a global shortage in electrical generating capacity.

  • Small modular reactors (SMRs) and utility-scale new builds are accelerating, with $37 million in SMR orders last year and a strong pipeline for future growth.

  • Paragon acquisition is fueling 25% expected growth, focusing on replacement parts and instrumentation for the North American fleet.

  • International expansion includes a sole supplier deal with EDF for 8–14 reactors in France and growing opportunities in Poland, North Africa, the Arab Gulf, and Ukraine.

  • The installed base is experiencing double-digit organic growth, with operators prioritizing life extension, capacity upgrades, and digital modernization.

Financial performance and guidance

  • Achieved record orders, backlog, margin expansion, and free cash flow conversion in the past year.

  • Guidance for 2026 anticipates accelerating organic growth in both core segments, despite crosscurrents in laboratory and radiation therapy businesses.

  • Backlog remains stable year-over-year, with a $400 million large order pipeline and optimism for continued growth.

  • Free cash flow conversion improved to 57% of EBITDA, with a target of 60%+ and further productivity improvements expected.

  • Leverage is at 3.2x EBITDA, with a low cost of debt and a focus on smaller, accretive M&A to further strengthen the portfolio.

Segment updates and operational highlights

  • Radiation therapy business faced international softness and U.S. capital spending constraints, but fundamentals remain strong with new product launches expected to drive growth in 2026.

  • Nuclear medicine is positioned for double-digit growth, driven by advances in theranostics and radiopharmaceutical therapies, with strong software and equipment integration.

  • Medical segment delivered margins above 42% in Q4, with growth expected to continue, though at a more moderate pace.

  • Margin expansion in nuclear and safety is targeted to reach 30% EBITDA by 2028, leveraging procurement optimization, volume absorption, and AI-driven productivity.

  • Paragon and Sun Nuclear acquisitions demonstrate a track record of margin improvement through operational discipline and integration.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more